SENS logo

SENSEONICS HOLDINGS INC

SENSNASDAQ
πŸ† #2870 by market capEarnings Nov 9US Equity
β€”β€”
Quote unavailable
πŸ””
Track SENS
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$494M
Small Cap
πŸ“ˆRevenue Growth (YoY)
90.6%
High Growth
πŸ“ŠGross Margin
54.9%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
10.0x
Elevated
Otter Score
56
Fair
No chart data available for SENS.

Trading Snapshot

Day Range
β€”
52-Week Range
$4.79 – $10.64
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
52.9M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
$35M
Last Q Revenue
$14M
P/E Ratio
β€”
P/S Ratio
10.0x
EPS (TTM)
$-2.24
Dividend Yield
β€”
Dilution (1yr)
+25.2%
SENS logo

SENSEONICS HOLDINGS INC

SENS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$35Mβ–² +56.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.7%β–² +1785.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$68Mβ–Ό βˆ’8.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$60Mβ–Ό βˆ’3.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41.7Mβ–² +25.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$822Kβ–Ό βˆ’$14M YoY
StockOtter Β· stockotter.space

About SENSEONICS HOLDINGS INC

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100

Analyst Ratings

β“˜
Consensus
Buy
13 analysts
Strong Buy2
Buy7
Hold3
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.